Key Takeaways: I-Mab has appointed Raj Kannan as its new CEO, filling its top position 18 months after its last top executive quit The new CEO is an industry veteran who engineered sales of his previous two companies after bringing their first drugs to market, hinting that I-Mab could follow a similar path By Warren Yang
There’s no shortage of market-moving news these days about up-and-coming cancer drug maker I-Mab, whose stock is getting pulled every which way as a result. Read more on IMAB stock.